5-Amino-1-Methylquinolinium (NNMT inhibitor)
Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT)
At a glance
What it is: Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT).
Primary research applications:
- Investigational: obesity and metabolic disease (preclinical)
Editorial summary: 5-Amino-1MQ is not actually a peptide — it's a small-molecule NNMT inhibitor often marketed alongside peptides. Preclinical obesity data is interesting but there are no human trials. Inclusion here reflects how it's sold, not what it is.
What is 5-Amino-1MQ?
Despite being frequently marketed with peptides, 5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is overexpressed in adipose tissue in obesity and is hypothesized to be a metabolic target.[1]
Mechanism of action
NNMT catalyzes methylation of nicotinamide using S-adenosylmethionine (SAM). Inhibiting it is proposed to increase cellular SAM and NAD+ pools and reduce adipose tissue expansion. Preclinical data supports weight loss and metabolic improvements in obese mice.
What the research shows
The peer-reviewed literature on 5-Amino-1MQ is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Is a peptide | It's a small molecule (methylquinolinium salt), not a peptide | Unsupported |
| Promotes fat loss in humans | No human evidence | Preliminary |
| Increases NAD+ | Proposed mechanism; not validated in humans | Uncertain |
Reported user experiences
How the research describes administration
Taken orally in grey-market use; no validated clinical protocol.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Interesting target biology. Not a peptide. No human data. If it works in humans the way it works in obese mice, it would be genuinely useful — but that's a big 'if' without any clinical trials.
Frequently asked questions
Is 5-Amino-1MQ a peptide?
No. It's a small-molecule inhibitor of the enzyme NNMT. It's commonly marketed alongside peptides, which is why it appears on peptide-focused sites.
Does 5-Amino-1MQ actually work?
Rodent obesity models show effects. No human data confirms this translates.
References
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-62. https://pubmed.ncbi.nlm.nih.gov/24717514/
- Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. https://pubmed.ncbi.nlm.nih.gov/29155147/